A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04998747 · clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Amgen Decision to stop development of AMG 701 SC, not for safety reasons but for business reasons.

Conditions

Interventions

Sponsor

Amgen